Immatics N.V. - (IMTX) closed at $7.31 on October 29, 2026, down 0.5% from the previous close, on volume of 1,124,245 shares (30-day average 980,835).
Data as of October 29, 2026.
29-Oct-2026
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Mon, 26-Oct 10:30 AM ET)
Immatics Posts Strong PRAME-Targeted Data for IMA402 and IMA203CD8 at 2026 ESMO
TipRanks (Mon, 26-Oct 7:57 AM ET)
Immatics (IMTX) Gets a Buy from Bank of America Securities
TipRanks (Mon, 26-Oct 6:40 AM ET)
Globe Newswire (Sat, 24-Oct 2:30 AM ET)
Immatics’ $150 Million Underwritten Offering Set to Fuel PRAME-Targeted Cancer Therapies
Market Chameleon (Tue, 25-Aug 5:15 AM ET)
Immatics Announces $150 Million Underwritten Offering
Globe Newswire (Tue, 25-Aug 7:00 AM ET)
Immatics Announces Second Quarter 2026 Financial Results and Business Update
Globe Newswire (Tue, 18-Aug 7:00 AM ET)
Market Chameleon (Mon, 17-Nov 2:09 AM ET)
Market Chameleon (Wed, 12-Nov 2:08 AM ET)
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Immatics N.V. - trades on the NASDAQ stock market under the symbol IMTX.
As of October 29, 2026, IMTX stock price declined to $7.31 with 1,124,245 million shares trading.
IMTX has a beta of 1.66, meaning it tends to be more sensitive to market movements. IMTX has a correlation of 0.21 to the broad based SPY ETF.
IMTX has a market cap of $1.11 billion. This is considered a Small Cap stock.
Last quarter Immatics N.V. - reported $11 million in Revenue and -$.53 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.10.
In the last 3 years, IMTX traded as high as $13.77 and as low as $3.30.
The top ETF exchange traded funds that IMTX belongs to (by Net Assets): SPDW, SBIO, KOMP, CANC, ONEQ.
IMTX has underperformed the market in the last year with a return of -29.3%, while the SPY ETF gained +13.0%. In the last 3 month period, IMTX fell short of the market, returning -18.7%, while SPY returned +5.7%. However, in the most recent 2 weeks IMTX has outperformed the stock market by returning +2.4%, while SPY returned -0.3%.
IMTX support price is $7.05 and resistance is $7.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMTX shares will trade within this expected range on the day.
